This early internal pilot study involved 30 female patients with newly diagnosed metastatic breast, lung, or colorectal cancer. The research team aimed to test whether it is possible to collect a wide range of health data over time, including clinical details, molecular markers, physiological signs, and behavioral information. The goal was to see if this integrated approach could work for future research on disease progression.
The study found high success rates in gathering the planned data. All patients completed their scheduled clinical visits, and tumor biopsies were obtained from everyone. Plasma collections were completed in 97.4% of cases, while stool samples were collected in 80.7% of cases. Wearable devices captured activity data for 95% of patient-days, heart rate for 84.2%, sleep for 90.6%, and blood oxygen levels for 70.7% of patient-days. Mobile app engagement for reporting pain and emotions also exceeded 80%.
Biospecimen quality control met all predefined metrics across different types of molecular testing. No adverse events, serious adverse events, discontinuations, or tolerability issues were reported during this initial phase. However, this study only enrolled 10% of the originally planned 300 participants. These feasibility results do not evaluate the clinical benefit of any genomically matched therapies, nor do they predict final patient outcomes.
Readers should understand that this report establishes a framework for future analyses rather than providing immediate clinical answers. The data collection methods appear workable, but the study is too early to draw conclusions about treatment effectiveness. Future research will need to enroll more patients to determine if these methods can reliably characterize disease trajectories and define molecular determinants of outcomes.